Abstract:FXR agonistic activity screening was conducted based on natural product resources containing 38 structurally diverse sesquiterpenoids isolated from Xylopia vielana. Among them, 34 undescribed sesquiterpenoids with 5 different skeleton types were first characterized by HRESIMS, NMR data, ECD calculations and X-ray crystallographic analysis. High-content screening for FXR agonistic activity of these compounds demonstrated that 13 compounds could activate FXR. Then molecular docking results suggested that hydrogen bonding and hydrophobic interactions might contribute to the main interaction of active compounds with FXR. The preliminary structure-activity relationships (SARs) of those isolates were also discussed. The most potent compound 27 significantly elevated the transcriptional activity of the FXR target gene BSEP promoter (EC50 = 14.26 μM) by a dual-luciferase reporter assay. Western blotting indicated that compound 27 activated the FXR-associated pathway, thereby upregulating SHP and BSEP expression, and downregulating CYP7A1 and NTCP expression. We further revealed that FXR was the target protein of compound 27 through diverse target validation methods, including CETSA, SIP, and DARTS under the intervention of temperature, organic reagents and protease. Pharmacological in vivo experiments showed that compound 27 effectively ameliorated α-naphthyl isothiocyanate (ANIT)-induced cholestasis in mice, as evidenced by the ameliorative histopathology of the liver and the decrease in biochemical markers: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total bilirubin (TBIL), direct bilirubin (DBIL), and total bile acid (TBA). This work showed a practical strategy for the discovery of new FXR agonists from natural products and provided potential insights for sesquiterpenoids as FXR agonist lead compounds.

Discovery of Two flavonoids as Agonists of G Protein-Coupled Receptor-35

Discovery of 2H-Chromen-2-one Derivatives As G Protein-Coupled Receptor-35 Agonists

Development and Characterization of Fluorescent Probes for the G Protein-Coupled Receptor 35.

Structure-Activity Relationship Studies of Coumarin-like Diacid Derivatives As Human G Protein-Coupled Receptor-35 (hgpr35) Agonists and a Consequent New Design Principle.

Discovery of (S)-3-(4-(benzyloxy)phenyl)-2-(2-phenoxyacetamido)propanoic Acid Derivatives As a New Class of GPR34 Antagonists.

SAR Studies of N-[2-(1H-Tetrazol-5-yl)phenyl]benzamide Derivatives As Potent G Protein-Coupled Receptor-35 Agonists.

Fluorescent Ligand-Based Discovery of Small-Molecule Sulfonamide Agonists for GPR120.

Design, Synthesis and Biological Activity of Flavonoid Derivatives As Selective Agonists for Neuromedin U 2 Receptor.

G蛋白偶联受体40激动剂TAK-875亚砜类似物的合成、绝对构型确证及生物活性研究

Identification of GPR35-associated Metabolic Characteristics Through LC-MS/MS-based Metabolomics and Lipidomics

Recent advances in GPR35 pharmacology; 5-HIAA serotonin metabolite becomes a ligand

Optimization of a peptide ligand for the adhesion GPCR ADGRG2 provides a potent tool to explore receptor biology

3D-QSAR and Molecular Docking Studies of Novel GPR52 Agonists

Discovery And Optimization Of Potent Gpr40 Full Agonists Containing Tricyclic Spirocycles

Synthesis and biological evaluation of 3-aryl-3-(4-phenoxy)-propionic acid as a novel series of G protein-coupled receptor 40 agonists.

Identification of natural products as novel ligands for the human 5-HT 2C receptor

Establishment of GPR41 Stable Cell Line and Agonist Screening of GPR41 Receptor

Synthesis and Biological Evaluation of 1, 2, 4-Oxadiazole Derivatives As Novel Gpr119 Agonists

Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,5-dimethylisoxazole.

The discovery of a new potent FXR agonist based on natural product screening

An efficient multistep ligand-based virtual screening approach for GPR40 agonists